Clinical Trials Logo
  1. Home
  2. Large B-cell Lymphoma
  3. NCT04690192

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Large B-cell Lymphoma Clinical Trial

Official title:
CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma

Clinical Trial Summary

The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.

Clinical Trial Description

This is a single-center, non-randomized, open-label, prospective clinical trial to evaluate the safety and efficacy of CNCT19 infusion following high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT) in patients with relapsed or refractory B-cell lymphoma. CNCT19 cells will be infused on day +3 (±1d) with a fixed dose of 2×10^6/kg. The study will assess the safety and efficacy of this combinational therapy, including the incidence and severity of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematological, and other non-hematological toxicities, and objective response rates and complete response rates and survivals of the subjects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04690192
Study type Interventional
Source Institute of Hematology & Blood Diseases Hospital, China
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date January 1, 2021
Completion date December 30, 2024
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05929716 - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Phase 2
Recruiting NCT05464719 - A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Phase 2
Recruiting NCT06047080 - An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Phase 3
Active, not recruiting NCT04566978 - 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) Early Phase 1
Recruiting NCT06104592 - Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Phase 2
Recruiting NCT04889716 - CAR-T Followed by Bispecific Antibodies Phase 2
Recruiting NCT04250324 - Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma Phase 1
Recruiting NCT05326243 - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT05794958 - Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Phase 1
Recruiting NCT06285422 - Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) Phase 1
Recruiting NCT05404048 - PD-L1 PET-imaging During CAR T-cell Therapy Phase 2
Not yet recruiting NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT06375733 - A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL Phase 1/Phase 2
Recruiting NCT05887167 - Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies Phase 1
Recruiting NCT05648019 - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Phase 2
Recruiting NCT05643742 - A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies Phase 1/Phase 2
Recruiting NCT05820841 - Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma Phase 3
Recruiting NCT05472610 - Study of Efficacy of BZ019 in Large B-cell Lymphoma Phase 2
Recruiting NCT03960840 - Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL Phase 1/Phase 2
Not yet recruiting NCT06356129 - Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Phase 3